Hemlibra (emicizumab-kxwh) prior authorization for Hemophilia A
Customize your policy alerts
Sign up for all medimpact policy alerts
Know when medimpact releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization (PA) criteria and renewal requirements for Hemlibra for Kentucky Medicaid members, including approval durations, clinical documentation, therapy transition and breakthrough bleed protocols. Affects prescribers and pharmacy prior authorization processes for Kentucky Medicaid (Commonwealth of Kentucky DMS).
New prior authorization criteria for Hemlibra (emicizumab-kxwh) will be effective July 1, 2025 for Kentucky Medicaid.
Detailed initial approval criteria for Hemophilia A with and without Factor VIII inhibitors including documentation requirements, weight documentation, therapy transition and breakthrough bleed protocols.
Renewal criteria requiring attestation of clinical benefit, current inhibitor status, recent weight, non-concomitant prophylactic use of Factor VIII, and dose within FDA limits.
Coverage Criteria for Hemlibra (emicizumab-kxwh)
Initial Therapy — Hemophilia A WITH Factor VIII inhibitors
Initial Approval — Hemophilia A WITH Factor VIII inhibitors: Covered when ALL of the following are met
Initial Therapy — Hemophilia A WITHOUT Factor VIII inhibitors
Initial Approval — Hemophilia A WITHOUT Factor VIII inhibitors: Covered when ALL of the following are met
Renewal Therapy
Renewal Criteria: Covered when ALL of the following are met
Approval duration: 1 year
Prophylactic concurrent use of Hemlibra (emicizumab-kxwh) with prophylactic Factor VIII products or prophylactic bypassing agents is not permitted beyond the defined short-term transition period. During transition, short-term overlap may occur to maintain bleed protection, but after transition Hemlibra must not be used in combination with prophylactic Factor VIII or bypassing agents. Prophylactic bypassing agents must be discontinued at least 24 hours prior to starting Hemlibra, and prophylactic Factor VIII replacement products must be discontinued within 7 days after starting Hemlibra. On‑demand use of Factor VIII products for acute bleeds is permitted per the breakthrough bleed protocol.
Short-term transition overlap with prophylactic Factor VIII or prophylactic bypassing agents is allowed when initiating Hemlibra to ensure continuous bleed protection. For patients with Factor VIII inhibitors, overlap with prophylactic bypassing agents or Factor VIII may be used during transition; prophylactic bypassing agents should be stopped ≥ 24 hours before Hemlibra start and prophylactic Factor VIII discontinued within 7 days after Hemlibra initiation. For patients without inhibitors, short-term overlap with prophylactic Factor VIII may occur during transition, but Hemlibra must not be continued in combination with prophylactic Factor VIII or bypassing agents after transition. Providers should follow the specified transition and breakthrough bleed protocols when documenting prior authorization requests.
Initial Therapy Requirements
Initial Therapy — grouped initial approval requirements (with/without inhibitors)
Initial approval requirements for patients with or without Factor VIII inhibitors: Covered when ALL of the following are met
Continuation (Renewal) Criteria
Continuation Therapy — Renewal requirements
Continuation / Renewal requirements: Covered when ALL of the following are met
Approval duration: 1 year
Coding and Documentation
| BIN: 023880 / PCN: KYPROD1 / GROUP: KYM01 | Kentucky MCO pharmacy routing |
| BIN: 026309 / PCN: KYPROD1 / GROUP: KYF01 | Kentucky FFS pharmacy routing |
Provider Responsibilities and Prior Authorization Actions
Hemlibra PA effective date and grandfathering
Hemlibra (emicizumab-kxwh) requires prior authorization for Kentucky Medicaid members effective July 1, 2025. Members with at least one paid Hemlibra claim within the 90 days prior to July 1, 2025 (April 2, 2025 through June 30, 2025) are grandfathered and will be provided an authorization through October 1, 2025.
Transition overlap allowance (short-term only)
Short-term overlap with prophylactic agents is permitted during the transition to Hemlibra to ensure continuous bleed protection, but Hemlibra must not be used in combination with prophylactic Factor VIII or prophylactic bypassing agents after the transition period.
- Prophylactic bypassing agents should be discontinued at least 24 hours prior to starting Hemlibra.
- Prophylactic Factor VIII replacement products should be discontinued within 7 days after starting Hemlibra.
Documentation required from prescriber
Prescriber must provide documentation of Factor VIII inhibitor status and the patient's current body weight as part of the PA request, and include chart notes or summaries as applicable; inhibitor status should be supported by a lab result within the past year and weight documentation should be within the last 6 months.
- Documentation confirming presence or absence of Factor VIII inhibitors (e.g., lab result within the past year).
- Documentation of current body weight (e.g., chart notes or summary within the last 6 months).
- For renewals, chart notes or summaries demonstrating clinical benefit compared to baseline are required.
Denial risk if required documentation not provided
PA may be denied if required documentation is not provided, including an inhibitor status lab within the past year or current weight documentation within the last 6 months, if the requested dose exceeds the FDA‑approved maximum, or if the provider does not attest to the required transition and breakthrough bleed protocols.
- Missing inhibitor status lab result (within past year) risks denial.
- Missing current weight documentation (within last 6 months) risks denial.
- Failure to attest to transition protocol or breakthrough bleed protocol may result in denial.
- Requests for doses exceeding the maximum FDA‑approved dose may be denied.
Definitions and Safety Monitoring
Background
Hemlibra (emicizumab-kxwh) is indicated for prophylactic treatment to prevent or reduce bleeding episodes in patients with Hemophilia A. The PA criteria distinguish management when Factor VIII inhibitors are present versus absent: both pathways require documentation of inhibitor status (e.g., lab within the past year), documentation of current body weight (within the last 6 months), provider attestation to transition and breakthrough bleed protocols, and that the requested dose does not exceed the maximum FDA‑approved dosing for the condition. Monitoring for thrombotic microangiopathy (TMA) or thromboembolism is noted as part of patient management.
Step Therapy / Transition Guidance
| Situation | Guidance |
|---|---|
| Short-term transition overlap | |
| During transition to Hemlibra, short-term overlap with prophylactic bypassing agents or Factor VIII is permitted to ensure continuous bleed protection; after the transition period, Hemlibra must not be used in combination with prophylactic Factor VIII or prophylactic bypassing agents. |
Quantity and Dosing Limits
Site of Care
No site-specific restrictions (infusion center guidance)
No site-of-care or infusion center-specific restrictions are imposed; the transition and on‑demand factor use guidance applies across care settings.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.